Literature DB >> 19399775

Quantification of hepcidin using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Sukhvinder S Bansal1, John M Halket, Jane Fusova, Adrian Bomford, Robert J Simpson, Nisha Vasavda, Swee Lay Thein, Robert C Hider.   

Abstract

Hepcidin is known to be a key systemic iron-regulatory hormone which has been demonstrated to be associated with a number of iron disorders. Hepcidin concentrations are increased in inflammation and suppressed in hemochromatosis. In view of the role of hepcidin in disease, its potential as a diagnostic tool in a clinical setting is evident. This study describes the development of a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) assay for the quantitative determination of hepcidin concentrations in clinical samples. A stable isotope labeled hepcidin was prepared as an internal standard and a standard quantity was added to urine samples. Extraction was performed with weak cation-exchange magnetic nanoparticles. The basic peptides were eluted from the magnetic nanoparticles using a matrix solution directly onto a target plate and analyzed by MALDI-TOF MS to determine the concentration of hepcidin. The assay was validated in charcoal stripped urine, and good recovery (70-80%) was obtained, as were limit of quantitation data (5 nmol/L), accuracy (RE <10%), precision (CV <21%), within -day repeatability (CV <13%) and between-day repeatability (CV <21%). Urine hepcidin levels were 10 nmol/mmol creatinine in healthy controls, with reduced levels in hereditary hemochromatosis (P < 0.000005) and elevated levels in inflammation (P < 0.0007). In summary a validated method has been developed for the determination of hepcidin concentrations in clinical samples. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399775     DOI: 10.1002/rcm.4033

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  10 in total

Review 1.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

2.  Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method.

Authors:  Sun-Il Hwang; Yong-Yook Lee; Jung-Ok Park; H James Norton; Elene Clemens; Laura W Schrum; Herbert L Bonkovsky
Journal:  Clin Chim Acta       Date:  2011-08-16       Impact factor: 3.786

3.  Hepcidin in beta-thalassemia.

Authors:  Elizabeta Nemeth
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

4.  Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids.

Authors:  Jia Fan; Shiwen Niu; Ailian Dong; Jian Shi; Hung-Jen Wu; Daniel H Fine; Yaping Tian; Chunxi Zhou; Xuewu Liu; Tong Sun; Gregory J Anderson; Mauro Ferrari; Guangjun Nie; Ye Hu; Yuliang Zhao
Journal:  Nanomedicine       Date:  2014-02-22       Impact factor: 5.307

5.  Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.

Authors:  John B Porter; Patrick B Walter; Lynne D Neumayr; Patricia Evans; Sukhvinder Bansal; Maciej Garbowski; Marcela G Weyhmiller; Paul R Harmatz; John C Wood; Jeffery L Miller; Colleen Byrnes; Guenter Weiss; Markus Seifert; Regine Grosse; Dagmar Grabowski; Angelica Schmidt; Roland Fischer; Peter Nielsen; Charlotte Niemeyer; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2014-09-11       Impact factor: 6.998

6.  High-throughput matrix-assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification of hepcidin in human urine.

Authors:  Damon S Anderson; Matthew M Heeney; Udo Roth; Christoph Menzel; Mark D Fleming; Hanno Steen
Journal:  Anal Chem       Date:  2010-02-15       Impact factor: 6.986

7.  Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.

Authors:  John B Porter; Maria Domenica Cappellini; Antonis Kattamis; Vip Viprakasit; Khaled M Musallam; Zewen Zhu; Ali T Taher
Journal:  Br J Haematol       Date:  2016-12-05       Impact factor: 6.998

8.  Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.

Authors:  Elizabeta Nemeth
Journal:  Adv Hematol       Date:  2009-12-24

9.  Role of hepcidin in the pathophysiology and diagnosis of anemia.

Authors:  Guido D'Angelo
Journal:  Blood Res       Date:  2013-03-25

10.  Copper(II) binding properties of hepcidin.

Authors:  Kanokwan Kulprachakarn; Yu-Lin Chen; Xiaole Kong; Maria C Arno; Robert C Hider; Somdet Srichairatanakool; Sukhvinder S Bansal
Journal:  J Biol Inorg Chem       Date:  2016-02-16       Impact factor: 3.358

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.